Our Q3 2024 financial results
October 31, 2024
Merck’s (NYSE: MRK) Q3 2024 financial results represent strong progress across the business and our diverse pipeline. Our company announced worldwide sales of $16.7 billion, an increase of 4% from Q3 2023.
“Our third-quarter results were strong, as we continue to make progress heading into 2025 and beyond,” said Rob Davis, chairman and chief executive officer. “Our pipeline is advancing and expanding, demonstrating our success in creating a sustainable innovation engine, and positioning Merck with a more diversified portfolio to drive growth. I continue to remain confident in the strength of our business and our ability to execute, and I want to thank our colleagues across the globe for their focus and commitment as we work to create lasting value for patients, shareholders and all our stakeholders.”
Merck anticipates full-year 2024 worldwide sales to be between $63.6 billion and $64.1 billion.
Find more details on Q3 2024 results below.
